Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats

被引:67
作者
Kamada, M [1 ]
Hirayama, F [1 ]
Udo, K [1 ]
Yano, H [1 ]
Arima, H [1 ]
Uekama, K [1 ]
机构
[1] Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 8620973, Japan
关键词
ketoprofen; cyclodextrin conjugate; delayed release; sustained release; repeated-release; colon-specific delivery; antiinflammatory effect;
D O I
10.1016/S0168-3659(02)00171-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
6(A)-O-[2-(3-Benzoylphenyl)propinoyl]-alpha-cyclodextrin (KP-alpha-CyD conjugate), in which an anti-inflammatory drug, ketoprofen (KP), is covalently bound to one of the primary hydroxyl groups of alpha-cyclodextrin, was prepared, and its release behavior in vitro and in vivo was investigated. Further, the CyD conjugate-based repeated- and prolonged-release systems were designed by combining the conjugate (used as a delayed-release fraction) with the KP-2-hydroxypropyl-beta-CyD (HP-beta-CyD) complex (used as a fast-release fraction) or with KP-ethylcellulose (EC) solid dispersion (used as a slow-release fraction), respectively. The conjugate released KP only in rat cecum and colonic contents, whereas it was stable in other biological fluids of rats. The conjugate showed a typical delayed-release pattern after oral administration to rats, i.e., plasma levels of KP increased after a lag time of about 3 h and reached a maximum concentration at about 7 h. On the other hand, the non-covalent inclusion complex of KP with HP-beta-CyD gave a rapid increase in plasma drug levels, and the KP-EC solid dispersion retarded slightly the increase of plasma levels. The co-administration of the conjugate and the HP-beta-CyD complex gave a typical repeated release profile, i.e., double peaks were observed at about 1-2 and 8-12 h in plasma KP levels. On the other hand, the co-administration of the conjugate and the EC solid dispersion gave a typical sustained-release pattern of KP, i.e., a constant plasma KP level was maintained for at least 24 h. These repeated or long circulating release patterns in plasma KP levels after oral administration were clearly reflected in the anti-inflammatory effect using rats with carageenan-induced acute edema in paw. The results suggest that various release-controlled preparations can be designed by employing CyD conjugates in combination with other carriers with different releasing properties. (C) 2002 Elsevier Science BV All rights reserved.
引用
收藏
页码:407 / 416
页数:10
相关论文
共 25 条
[1]  
ABAS A, 1987, J PHARMACOL EXP THER, V240, P637
[2]   Cyclodextrin derivatives in pharmaceutics [J].
Albers, E ;
Muller, BW .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04) :311-337
[3]   AN INTRAVENOUS TOXICITY STUDY OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN, A USEFUL DRUG SOLUBILIZER, IN RATS AND MONKEYS [J].
BREWSTER, ME ;
ESTES, KS ;
BODOR, N .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 59 (03) :231-243
[4]   CHIRAL DIFFERENTIATION IN THE DEACYLATION OF 6A-O-(2-[4-(2-METHYLPROPYL)PHENYL]PROPANOYL)-BETA-CYCLODEXTRIN [J].
COATES, JH ;
EASTON, CJ ;
VANEYK, SJ ;
MAY, BL ;
SINGH, P ;
LINCOLN, SF .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1991, (11) :759-760
[5]  
Duchene D., 1991, NEW TRENDS CYCLODEXT
[6]  
Haeberlin B, 1992, ORAL COLON SPECIFIC, P1
[7]  
HASHIDA M, 1998, FORMULATION DESIGN O
[8]  
Hirayama F, 2000, J PHARM SCI, V89, P1486, DOI 10.1002/1520-6017(200011)89:11<1486::AID-JPS11>3.3.CO
[9]  
2-4
[10]   Cyclodextrin-based controlled drug release system [J].
Hirayama, F ;
Uekama, K .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (01) :125-141